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ABSTRACT
Objective: Although blood–brain barrier (BBB) impairment has been reported in HIV-infected in-
dividuals, characterization of this impairment has not been clearly defined.
Methods: BBB integrity was measured by CSF/plasma albumin ratio in this cross-sectional study of
631 HIV-infected individuals and 71 controls. We also analyzed CSF and blood HIV RNA and neo-
pterin, CSF leukocyte count, and neurofilament light chain protein (NFL) concentrations. The HIV-
infected participants included untreated neuroasymptomatic patients, patients with untreated
HIV-associated dementia (HAD), and participants on suppressive antiretroviral treatment (ART).
Results: The albumin ratio was significantly increased in patients with HAD compared to all other
groups. There were no significant differences between untreated neuroasymptomatic partici-
pants, treated participants, and controls. BBB integrity, however, correlated significantly with
CSF leukocyte count, CSF HIV RNA, serum and CSF neopterin, and age in untreated neuroasymp-
tomatic participants. In a multiple linear regression analysis, age, CSF neopterin, and CSF leuko-
cyte count stood out as independent predictors of albumin ratio. A significant correlation was
found between albumin ratio and CSF NFL in untreated neuroasymptomatic patients and in par-
ticipants on ART. Albumin ratio, age, and CD4 cell count were confirmed as independent predic-
tors of CSF NFL in multivariable analysis.
Conclusions: BBB disruption was mainly found in patients with HAD, where BBB damage corre-
lated with CNS immunoactivation. Albumin ratios also correlated with CSF inflammatory markers
and NFL in untreated neuroasymptomatic participants. These findings give support to the asso-
ciation among BBB deterioration, intrathecal immunoactivation, and neuronal injury in untreated
neuroasymptomatic HIV-infected individuals. Neurol Neuroimmunol Neuroinflamm 2016;3:e300; doi:
10.1212/NXI.0000000000000300
GLOSSARY
ART 5 antiretroviral therapy; BBB 5 blood–brain barrier; HAD 5 HIV-associated dementia; NFL 5 neurofilament light chain
protein.
Impairment of the blood–brain barrier (BBB) is common in patients with HIV encephalitis and
important in the pathogenesis of HIV-associated dementia (HAD),1,2 but its characterization is
incomplete.
CSF viral load and intrathecal immunoactivation, as determined by increased CSF neopterin,
correlate with BBB impairment.3,4 CNS inflammation also correlates with axonal injury, as
measured by CSF concentrations of the light subunit of neurofilament protein (NFL).5These
findings indicate an association among neuroinflammation, BBB permeability, and neuronal
injury, but their relationship has not been fully elucidated.
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Initiation of antiretroviral therapy (ART)
reduces CSF HIV RNA6 and various markers
of inflammation and neuronal injury.5,7 In
a study with 38 neuroasymptomatic individ-
uals,8 only 5% (2/38) had elevated albumin
ratios prior to ART initiation: both normal-
ized on treatment. In a recent cross-sectional
study, 38.6% of untreated and 24.6% of
treated participants had signs of BBB
impairment.9
The purpose of this study was to define the
prevalence of BBB disruption in a large num-
ber of treated and untreated HIV-infected in-
dividuals at different stages of infection and
CNS injury. To test the hypothesis that BBB
function is associated with neuroinflammation
and CNS injury in HIV, we analyzed associa-
tions between albumin ratios and markers of
CNS immunoactivation and neuronal injury
in samples from predefined patient groups
representing essential stages of HIV disease
progression and viral suppression.
METHODS Patients. In this retrospective cross-sectional
study, we analyzed archived CSF samples from 631 HIV-
infected adults and 71 HIV-negative controls from 3 centers
(Gothenburg, Sweden; San Francisco, CA; and Sydney,
Australia). Neurocognitive testing was not routinely performed
on participants without any neurologic symptoms or complaints.
All participants were clinically assessed for neurologic and
neurocognitive symptoms. Those without neurologic complaints
or signs at inclusion are referred to as neuroasymptomatic
participants. HIV-infected participants were divided into 7
HIV-infected groups: untreated neuroasymptomatic participants,
stratified into 4 groups according to CD4 level; untreated
participants with HAD, stratified into 2 groups according to
severity of dementia; and participants on ART (table 1).
The neuroasymptomatic untreated groups were as follows:
(1) neuroasymptomatic with CD41 T-cell count .350 (n 5
125); (2) neuroasymptomatic with CD41 T-cell count 200–
349 (n 5 117); (3) neuroasymptomatic with CD41 T-cell
count 50–199 (n 5 102); and (4) neuroasymptomatic with
CD41 T-cell count ,50 (n 5 71) cells/mL.5 The 2 groups of
patients with HAD were (5) untreated patients with HAD
stage 110 (n 5 24) and (6) untreated patients with HAD stage
2–4 (n 5 33). The final group (7) consisted of participants on
ART with plasma HIV RNA ,50 copies/mL for $6 months
(n 5 159). Individuals with CNS opportunistic or other infections,
CNS neoplasms, acute cranial nerve paresis, or neurologic diseases
with CNS involvement, were excluded. The diagnosis of HAD was
based on Centers for Disease Control and Prevention and American
Academy of Neurology Task Force Criteria using standard laboratory,
neuropsychological testing, and clinical evaluations.11,12 Most of the
participants were studied before publication of the formal Frascati
criteria11 and were diagnosed with AIDS dementia complex stages
1–410: they met the functional criteria for the Frascati diagnosis of
HAD without the requisite extensive formal neuropsychological
assessment.
Standard protocol approvals, registrations, and patient
consents. CSF samples were obtained under the auspices of
research protocols approved by the institutional review boards
of each of the study sites and in accordance with the Helsinki
Declaration, either within the context of studies of the natural
history of HIV infection (neuroasymptomatic participants and
participants on ART) or during diagnostic evaluations (patients
with HAD). All participants gave informed consent, and if their
capacity to provide consent was questioned, consent was also ob-
tained from those with power of attorney.
Methods. Quantitative determination of CSF and plasma albu-
min was performed by nephelometry (Behring Nephelometer
Analyser, Behringwerke AG, Marburg, Germany). The albumin
ratio was calculated as CSF albumin (mg/L)/plasma albumin
(g/L) and used to evaluate BBB function. Reference values were
,6.8 for individuals younger than 45 years and ,10.2 for indi-
viduals $45 years of age.13 Some CSF samples had been frozen,
but never refrozen: regular controls with analyses of biological
markers have confirmed compatibility between fresh and frozen
samples.
CSF neopterin was analyzed using a commercially available
immunoassay (BRAHMS, Berlin, Germany) according to the
manufacturer’s instructions. Normal CSF neopterin reference
Table 1 Patient characteristics
Groups No.
Age, y,
median (IQR)
Plasma HIV RNA,
median log10 (IQR)
CSF HIV RNA, median
log10 (IQR)
Blood CD41 T cells,
cells/mL, median (IQR)
Cross-sectional study
Controls 71 43 (35–49) — — 833 (674–1,033)
NA, CD4 >350 125 38 (30–46) 4.12 (3.40–4.55) 3.17 (2.33–3.91) 502 (421–650)
NA, CD4 200–349 117 39 (31–47) 4.77 (4.24–5.17) 3.97 (3.42–4.45) 256 (234–300)
NA, CD4 50–199 102 37 (32–47) 4.92 (4.46–5.42) 3.90 (3.31–4.51) 120 (84–163)
NA, CD4 <50 71 38 (33–47) 5.20 (4.53–5.54) 3.07 (2.25–3.76) 20 (10–37)
HAD stage 1 24 39 (32–44) 5.24 (4.48–5.57) 3.78 (2.57–4.82) 55 (21–152)
HAD stage 2–4 33 40 (34–46) 4.94 (4.07–5.44) 4.94 (4.17–5.44) 130 (18–195)
ART 159 45 (37–52) ,1.70 ,1.70 490 (325–671)
Abbreviations: ART5 on antiretroviral treatment with P-RNA,50 copies/mL; HAD5 HIV-associated dementia (untreated);
IQR 5 interquartile range; NA 5 neuroasymptomatic (untreated).
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value was ,5.8 nmol/L.14 CSF concentrations of NFL were
measured by an enzymatic 2-site quantitative immunoassay
(NF-light ELISA kit; UmanDiagnostics AB, Umeå, Sweden).
The upper normal reference limits of CSF NFL were ,380
(18–30 years), ,560 (30–39 years), ,890 (40–59 years), and
,1,850 ng/L (.59 years).
HIV RNA levels in blood and CSF were quantified by the
Roche Amplicor Monitor version 1.5, Abbott RealTime HIV-1
assay (Abbott Laboratories, Abbott Park, IL), or Roche Taqman
assay version 1 or 2 (Hoffman La-Roche, Basel, Switzerland). The
lower limit of detection varied between 20 and 50 (1.70 log10)
HIV RNA copies/mL in the different assays. Blood CD41 T-cell
counts, CSF leukocytes, and CSF/blood albumin measurements
were performed in the local clinical laboratories.
Statistical analysis. Descriptive statistics were performed using
Prism (version 6.0, GraphPad, La Jolla, CA) or SPSS (version 20,
IBM, Armonk, NY) software. All continuous variables except age
and leukocyte count were log10 transformed to reduce skewness.
Differences between multiple groups were tested with ordinary
1-way analysis of variance with Tukey multiple comparisons post
hoc test; Student t test was used for comparisons between 2
groups. Associations were analyzed with Pearson correlation
coefficients. Predictors of albumin ratio and CSF NFL were
analyzed by multiple linear regression analysis with forward
selection.
RESULTS A total of 631 HIV-positive patients and
71 HIV-negative controls were studied (table 1).
Participants with HAD (stage 1–4 pooled) had
significantly higher albumin ratios compared with all
the other groups (p , 0.001) (figure 1 and table 2).
The highest albumin ratios were found in patients with
the most severe HAD (stages 2–4). Albumin ratios
were elevated above age-dependent reference values13
in 76% (25/33) of patients with HAD stage 2–4 and
in 58% (14/24) of patients with HAD stage 1. Sixty-
eight percent (39/57) of HAD participants had
elevated albumin ratios compared with 16% (66/415)
of untreated neuroasymptomatic participants. There
were no statistically significant differences in albumin
ratios between untreated neuroasymptomatic patients,
participants on ART, and HIV-negative controls.
Similarly, there were no significant differences in
albumin ratios among untreated neuroasymptomatic
participants with different CD4 cell strata: 12% with
CD41 T-cell count .350, 20% with CD4 count
200–349, 17% with CD4 count 50–199, and 15%
with CD4 count ,50 cells/mL had elevated albumin
ratios. Eleven percent of HIV-negative controls and
12% of participants on suppressive ART had elevated
albumin ratios.
In order to further characterize BBB impairment,
in neuroasymptomatic participants, we examined the
Figure 1 CSF/plasma albumin ratio in the
different groups of HIV-infected
participants and the healthy controls
Boxes encompass interquartile ranges with median (line)
and mean (1), while whiskers designate 10th to 90th
percentiles. Included in this cross-sectional analyses
were 71 controls (HIV2); HIV-infected neuroasympto-
matic participants without antiretroviral treatment
(ART) stratified according to levels of blood CD41 T-cell
count .350 (n 5 125), 200–349 (n 5 117), 50–199 (n 5
102), and,50 (n5 71); 57 participants with HIV-associated
dementia (HAD) staged according to severity of symptoms,
stage 1 (n 5 24) and stage 2–4 (n 5 33); and 159 partic-
ipants on ART $6 months and plasma HIV RNA ,50 cop-
ies/mL. Albumin ratios were significantly higher in patients
with HAD (stage 1–4 pooled) compared to all other groups
(p , 0.001).
Table 2 Albumin ratio, inflammatory markers, and CSF NFL in the different groups of HIV-infected participants and the healthy controls
Groups No.
Albumin ratio,
median (IQR)
S-neopterin, nmol/L,
median (IQR)
CSF-neopterin,
nmol/L, median (IQR)
CSF WBC, cells/mL,
median (IQR)
CSF NFL, ng/L,
median (IQR)
Controls 71 4.77 (3.91–6.37) 6.1 (4.3–8.2) 5.00 (4.1–6.4) 1 (0–2) 407 (331–537)
NA, CD4 >350 125 4.70 (3.53–6.40) 11.1 (8.4–17.9) 11.2 (8.1–17.7) 5 (3–9) 440 (272–580)
NA, CD4 200–349 117 5.15 (4.09–7.00) 18.2 (11.2–23.2) 18.3 (12.0–26.4) 6 (3–13) 395 (228–640)
NA, CD4 50–199 102 4.90 (3.79–6.86) 21.0 (13.6–32.7) 21.7 (12.4–32.4) 4 (1–9) 490 (295–886)
NA, CD4 <50 71 5.00 (3.76–6.21) 23.5 (16.5–37.8) 22.0 (11.5–35.0) 1 (0–2) 801 (477–2,380)
HAD stage 1 24 7.37 (5.26–11.31) 22.5 (17.0–33.8) 29.4 (24.6–61.5) 3 (2–9) 11,400 (5,224–38,225)
HAD stage 2–4 33 10.42 (7.20–17.00) 26.4 (18.2–38.9) 75.0 (34.7–127.5) 11 (4–26) 30,825 (25,898–35,753)
ART 159 4.70 (3.61–6.52) 8.4 (5.7–11.0) 6.7 (4.8–9.3) 0 (0–2) 454 (289–673)
Abbreviations: ART5 on antiretroviral treatment with P-RNA,50 copies/mL; HAD 5 HIV-associated dementia (untreated); IQR5 interquartile range; NA5
neuroasymptomatic (untreated); NFL 5 neurofilament light chain protein; WBC 5 white blood cells.
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CSF biomarker profiles in participants with increased
as opposed to normal albumin ratios with respect to
age-dependent reference values.
Neuroasymptomatic participants with increased
albumin ratios had higher CSF neopterin (p ,
0.05) and CSF NFL levels (p , 0.01). No difference
was found in CSF HIV RNA between those groups
(figure 2). Patients on suppressive ART and HIV-
negative controls with increased albumin ratios had
similar levels of CSF neopterin and CSF NFL as
participants with normal ratio (not shown).
Correlations of CSF biomarkers and albumin ratio. In
untreated neuroasymptomatic participants, albu-
min ratios correlated with CSF leukocyte count
(r 5 0.25, p , 0.001), CSF HIV RNA levels
(r 5 0.15, p , 0.01), blood neopterin (r 5 0.21,
p , 0.001), CSF neopterin (r 5 0.26, p , 0.001),
and age (r 5 0.24, p , 0.001). Similar correlations
with age (r5 0.27, p5 0.001) and CSF leukocytes
(r 5 0.16, p 5 0.05) were found in virally sup-
pressed participants. In HIV-negative controls,
only age correlated significantly with albumin
ratio (r 5 0.26, p , 0.05). No significant
correlations were found between CSF neopterin
and albumin ratio in participants on suppressive
ART or in HIV-negative controls. There was no
significant correlation between CD4 nadir and
albumin ratio in virally suppressed participants.
While all participants on ART had plasma HIV
RNA levels ,50 copies/mL as part of the inclusion
criteria, 5 out of 159 treated participants (3.1%) had
detectable HIV RNA levels in the CSF, ranging from
50 to 145 copies/mL.
In a multiple linear regression analysis, age, CSF
neopterin, and CSF leukocyte count stood out as
independent predictors of albumin ratios in neuroa-
symptomatic participants (table 3).
Correlations between albumin ratio and CSF NFL. A sig-
nificant correlation was found between the albumin
ratio and CSF NFL concentration in untreated neu-
roasymptomatic participants (r 5 0.32, p , 0.001).
Albumin ratio was confirmed as an independent
predictor of CSF NFL together with age and
CD4 cell count in a multiple linear regression anal-
ysis. By contrast, CSF HIV RNA and CSF neo-
pterin were not found to be significant predictors
(table 4).
Albumin ratios and CSF NFL levels were also cor-
related in participants on ART (r5 0.44, p, 0.001)
and albumin ratios were, together with age, con-
firmed as independent predictors of CSF NFL in
multivariable analysis (data not shown). Likewise,
a significant correlation was found between albumin
ratios and CSF NFL concentrations in HIV-negative
controls (r5 0.30, p, 0.05). CSF NFL results were
missing in the majority of patients with HAD because
of shortage of samples.
DISCUSSION BBB impairment is considered a key
event in CNS injury in HIV infection. To date, this
is the largest study that has characterized the BBB in
Figure 2 CSF biomarkers in HIV-infected
untreated neuroasymptomatic
participants with damaged and normal
blood–brain barrier (BBB)
Comparisons of CSF biomarkers in HIV-infected untreated
neuroasymptomatic participants with impaired (Alb ratio
1) and normal (Alb ratio 2) BBB function with respect to
age-dependent reference values. CSF HIV RNA levels did
not differ significantly between the groups (A) whereas
CSF neopterin (p , 0.05, B) and CSF neurofilament light
chain protein (NFL) (p , 0.01, C) were higher in partic-
ipants with impaired BBB compared with those with
normal BBB.
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treated and untreated HIV-infected individuals at
different stages of infection, and with varying
degrees of neurocognitive impairment. A majority
of the participants with HAD (68%) had elevated
albumin ratios, compared with 16% of untreated
neuroasymptomatic individuals. This is broadly
consistent with previous smaller studies, where the
prevalence of BBB dysfunction has been shown to
increase as the HIV infection progresses.3,15–17 In
contrast to earlier publications that have been fairly
small or based on case reports, this study extends
the characterization of BBB dysfunction and its
relationship to neuroinflammation and CNS injury
to this rather large cohort of thoroughly classified
participants with HIV infection. This is a major
strength of the study andmakes the results more reliable.
Although most neuroasymptomatic HIV-infected
participants without ART had albumin ratios within
the normal range, we found a significant correlation
between CSF neopterin, a marker of intrathecal
immune activation, and BBB integrity in this group.
CNS inflammation was, together with age, confirmed
in a multivariable analysis as independent predictors
of BBB impairment. Intrathecal immune activation
is a general feature of HIV infection, and a persistent
low-grade immune activation is often present even in
antiretroviral treated patients despite several years of
suppressed plasma viral loads.7,18 However, CSF neo-
pterin did not correlate with albumin ratios in pa-
tients on suppressive ART, or in healthy controls,
perhaps because substantial CNS inflammation is
required for BBB impairment.
In addition, we found the albumin ratio to be an
independent predictor of CSF NFL both in untreated
and treated HIV-infected individuals, suggesting
that minor impairment of the BBB might be harmful
to the CNS. However, the lack of association with
markers of immune activation in patients on treat-
ment implies either an additional mechanism or
possibly fixed BBB impairment as a legacy effect of
pre-ART disease. Another recent study on treated
HIV-infected individuals undergoing lumbar punctu-
res for clinical reasons reported a similar association
between albumin ratios and the neural protein
t-tau, but without any association with CSF neopter-
in.19 NFL is a more sensitive marker of neural injury
than t-tau20 and our study corroborates the associa-
tion between BBB function and CNS disturbance,
extending it also to untreated and treated HIV-
infected participants without neurologic symptoms.
The BBB is a semipermeable barrier surrounding
the CNS. Its main function is to maintain a stable
environment for the brain. It differs from other capil-
laries in the body in a number of ways. Most impor-
tantly, endothelial cells in the BBB are fused together
by tight junctions.21 HIV-infected cells in the CNS
and the periphery produce viral proteins such as
gp120, Tat, and Nef, and inflammatory mediators
including cytokines and chemokines.22 These viral
and host products have the ability to affect the integ-
rity of the BBB,23 leading to increased permeability of
the brain endothelial cells. Impairment of the BBB
could be harmful to the brain by facilitating influx of
blood proteins, viral particles, and other possibly neu-
rotoxic substances into the CNS (figure e-1 at
Neurology.org/nn). Conversely, BBB impairment
may facilitate entry of antiretroviral drugs, which
may be beneficial. The BBB restricts the entry of
proteins from the blood to the brain and the CSF,
Table 4 Univariable correlation (left columns)
and multiple linear regression (right
columns) determining predictors of CSF
NFL in 415 HIV-infected
neuroasymptomatic patients without
antiretroviral treatment
Predictor
Univariable Multivariable
Std ß (r) p Value Std ßadj p Value
Age 0.365 ,0.001 0.341 ,0.001
Blood CD4 20.326 ,0.001 20.392 ,0.001
CSF WBC 20.090 0.22
CSF HIV RNA 20.070 0.34
CSF neopterin 0.200 0.010
CSF/P albumin
ratio
0.315 ,0.001 0.264 ,0.001
Abbreviations: P 5 plasma; NFL 5 neurofilament light chain
protein; Std ß 5 standardized beta coefficient; Std ßadj 5
adjusted standardized beta coefficient; WBC 5 white blood
cells.
Table 3 Univariable correlation (left columns)
and multiple linear regression (right
columns) determining predictors of
CSF/plasma albumin ratio in 415 HIV-
infected neuroasymptomatic patients
without antiretroviral treatment
Predictor
Univariable Multivariable
Std ß (r) p Value Std ßadj p Value
Age 0.242 ,0.001 0.222 ,0.001
Blood CD4 0.010 0.84
Blood CD8 20.009 0.85
CSF WBC 0.245 ,0.001 0.132 0.015
P HIV RNA 0.097 0.055
CSF HIV RNA 0.153 0.002
S neopterin 0.208 ,0.001
CSF neopterin 0.259 ,0.001 0.187 0.001
Abbreviation: CSF 5 cerebrospinal fluid; P 5 plasma;
S 5 serum; Std ß 5 standardized beta coefficient;
Std ßadj 5 adjusted standardized beta coefficient; WBC 5
white blood cells.
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resulting in markedly lower concentrations of pro-
teins in CSF than in blood. Because albumin is exclu-
sively synthesized in the liver, albumin detected in
CSF originates from blood. The albumin ratio
between CSF and plasma provides a reliable determi-
nation of BBB function,13,24 and is the most com-
monly used method to examine this.
Myelinated axons consist of a major structural ele-
ment NFL, the light subunit of the neurofilament
protein. Previous studies have confirmed CSF NFL
concentrations as a reliable marker of CNS axonal
injury in various neurodegenerative diseases25 includ-
ing CNS injury associated with HIV infection.5,26
Increased CSF NFL is a consistent finding in patients
with HAD, but can also be found in some HIV-
infected patients without neurologic symptoms,
mainly in individuals with low CD41 T-cell counts.
Our study confirms immunosuppression and age as
predictors of CSF NFL in multivariable analysis. In
addition, we found that impairment of the BBB was
an independent predictor of axonal injury. A signifi-
cant correlation was found between the albumin ratio
and CSF NFL in both untreated and treated individ-
uals, supporting the hypothesis that increased BBB
permeability may be linked with neuronal injury in
HIV infection. Neurotoxic substances and inflamma-
tion may cause damage to neuroglial cells further
amplifying BBB breakdown, eventually leading to
clinically significant neurocognitive deficits.
In agreement with previous smaller studies,3 we
found no correlation between CD41 T-cell count
and BBB dysfunction. Another recent study found
that increased BBB permeability was more common
in individuals on ART with low CD4 nadir compared
with those with high CD4 nadir.9 We could not
confirm this finding in our study, where no correla-
tion was found between CD4 nadir and the albumin
ratio in patients on suppressive ART. In contrast to
the abovementioned study, all treated participants in
our study were virologically suppressed, which might
explain the diverse results. Furthermore, in the cur-
rent study, participants were asymptomatic, with
lumbar punctures performed within clinical study
protocols and not for clinical reasons.
Also in agreement with previous studies,9 we did
not find any difference in the albumin ratio between
neuroasymptomatic HIV-infected participants and pa-
tients on ART. However, those were cross-sectional
studies and the data are sparse on BBB integrity
changes following initiation of ART.8 Neither has
the effect of ART on BBB integrity in patients with
HAD and increased albumin ratios been carefully
elucidated. Smaller studies and case reports indicate
that normalization of the albumin ratio, even in
patients with HAD, is possible after commencement
of ART.8,27
Almost one-fifth of untreated neuroasymptomatic
participants, some of them with preserved immune
systems, had signs of BBB impairment. Patients in
the neuroasymptomatic groups had neither neuro-
logic nor neurocognitive symptoms, signs, or com-
plaints, but as neuropsychological testing was not
performed on all participants, we cannot exclude
the possibility that some had asymptomatic neuro-
cognitive impairment. It is not known if asymptom-
atic patients with elevated albumin ratios have an
increased risk of developing symptomatic neurocog-
nitive deficits in the future. It is notable that the pro-
portion of asymptomatic untreated patients with
impaired BBB had significantly higher levels of both
CSF neopterin and CSF NFL compared with patients
without BBB injury, while no such difference was
found in participants on suppressive ART or in
healthy controls.
We have previously found that CSF NFL can
predict severe neurocognitive impairment.28
Impairment of BBB with simultaneously raised lev-
els of CSF neopterin and CSF NFL give further
support to the association among BBB deteriora-
tion, neuroinflammation, and axonal injury in
untreated HIV. Indeed, our results point to the
potential utility of measurement of the albumin
ratio, something which is simple and easily per-
formed. Further, our data allow the generation of
2 important hypotheses. First, albumin ratio eleva-
tion in neuroasymptomatic patients may predict
the subsequent development of HIV-associated
neurocognitive disorders. Second, there is no need
for antiretroviral drugs that penetrate the brain if
the albumin ratio is normal. Further prospective
studies can address these hypotheses.
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